Finzati - Logo
OCS logo

Oculis Holding AG

OCSBiotechnology
$12.17
0.00 (0.00%)
Current price
EarningsLatest report: Mar 31, 2026
HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$716.88M
Growth
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.01Healthy liquidity · 5.96Weak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 11, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$12.17
Change0.00%
Shares Out58.91M
Market Cap$716.88M
52W Range10.52 - 34.48
Beta0.13
P/E-10.99
P/S0.00
P/B6.62
P/FCF-83.46
EV/Sales0.00
EV/EBITDA-53.40

Investment DNA

How strong this company looks for long-term investors

43
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
68/100
Why this score
Manageable debt level · 0.01Healthy liquidity · 5.96Weak profitability

Analyst view

Analyst sentiment and price target

OCS
Analyst sentiment
Based on 9 analyst votes · 2026-09-05
100/100
Bullish
Bullish
9
Hold
0
Bearish
0
Price Target
2026-06-26
Low
$26.00
Mean
$39.40
Median
$38.00
High
$50.00

Company Overview

IPO: 5/18/2021
Industry: Biotechnology
P/B i: 6.62
Debt / Equity i: 0.01
Operating Margin: 0.00%
Net Margin: 0.00%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.01
Current Ratio: 5.96
Quick Ratio: 5.96
Status: Good
🧾

No insider activity

No recent insider transactions available.